-
Piper Jaffray Gives Company Update On Watson Pharmaceuticals
Thursday, April 7, 2011 - 7:52am | 185Yesterday, detailed data from Watson Pharmaceuticals (NYSE: WPI) and partner Columbia Labs' successful Phase III study of Prochieve (progesterone gel) was published in the journal Ultrasound in Obstetrics & Gynecology. The data revealed an advantage for Prochieve in terms of neo-natal morbidity...
-
Wedbush Reiterates OP Rating, $23 PT On XNPT
Thursday, April 7, 2011 - 7:49am | 68Wedbush is reiterating its OP rating and $23 PT on shares of XenoPort, Inc. (NASDAQ: XNPT). XenoPort closed Wednesday at $6.38. “Our price target of $23/share is derived from a sum of the parts valuation,” Wedbush writes. “We do not include the potential for ex-U.S. royalties for any products,...
-
Benchmark Comments On Columbia Laboratories Pregnant Study Results
Thursday, April 7, 2011 - 7:49am | 119According to Benchmark, Columbia Laboratories (NASDAQ: CBRX) favorable results in pregnant study were published in the journal Ultrasound in Obstetrics and Gynecology. Benchmark reported that data shows treatment with Columbia's Prochieve reduced incidence of preterm birth 45% compared with...
-
Oppenheimer Has Outperform On Optimer Pharmaceuticals (OPTR)
Thursday, April 7, 2011 - 7:31am | 155Oppenheimer & Co. has an Outperform rating and a $17 price target on shares of Optimer Pharmaceuticals (NASDAQ: OPTR). In a note to clients, Oppenheimer writes, "On 4/6, OPTR announced a two-year co-promote agreement with CBST for DIFICID (fidaxomicin). We note that CBST entered into a similar...
-
GlaxoSmithKline and XenoPort: FDA Approval for Restless Leg Syndrome Drug Horizant (XNPT, GSK)
Thursday, April 7, 2011 - 7:21am | 431GlaxoSmithKline (NYSE: GSK) and XenoPort (NASDAQ: XNPT) announced Wednesday that the U.S. Food and Drug Administration has approved Horizant™ (gabapentin enacarbil) Extended-Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome in adults. Horizant is not recommended...
-
Deutsche Bank Raises PT On Medicis Pharmaceuticals To $40
Thursday, April 7, 2011 - 6:59am | 27Deutsche Bank has raised the price target on Medicis Pharmaceuticals (NYSE: MRX) from $36 t0 $40 and maintains its Buy rating.
-
Deutsche Bank Upgrades XenoPort To Buy, PT To $13
Thursday, April 7, 2011 - 6:48am | 27Deutsche Bank has upgraded XenoPort (NASDAQ: XNPT) from Hold to Buy and has raised the price target from $6 to $13.
-
RBC Capital Ups ELN To Outperform
Thursday, April 7, 2011 - 6:40am | 52Analysts at RBC Capital upgrade Elan Corporation plc (NYSE: ELN) from “sector perform” to “outperform.” The target price for ELN has been raised from $8 to $10. ELN shares gained 6.15% to close at $7.59 yesterday. More Analyst Ratings here
-
Buffett Bargains
Thursday, April 7, 2011 - 1:32am | 412Warren Buffett, head of Berkshire Hathaway (BRK-A) (BRK-B), has numerous fans, and a few critics. However, the critics don't have a much of a leg to stand on, especially when several of the stocks he owns traded at 52 week highs on Wednesday. If you look at the list of Warren Buffett Berkshire...
-
Mad Money Lightning Round: Cramer Advises Investors To Buy Fortune Brands (TEVA, SDRL, HCBK, FO, PUDA, BTU, BIDU, SINA, RVBD, HOC, WFT, EW)
Thursday, April 7, 2011 - 12:22am | 346On CNBC's Mad Money, Jim Cramer said during the Lightning Round that Teva Pharmaceutical (NASDAQ: TEVA) is a “mystery to me. That stock has been crushed. The health care stocks are going to bottom here." He believes that SeaDrill Limited (NYSE: SDRL) is “good. I like the oil drillers. There might...
-
4 Biotech Companies That Could Be Buyout Targets
Wednesday, April 6, 2011 - 2:26pm | 141We took a look at biotechnology stocks with promising pipelines. With the recent announcement of Valeant Pharmaceuticals (VRX) attempting a hostile takeover of Celphalon (CEPH), we have looked at other value names in the biotech sector that could be lucrative targets in the near future. We viewed...
-
10 Housing Stocks That Could Blast Higher This Summer
Wednesday, April 6, 2011 - 2:22pm | 141We took a look at biotechnology stocks with promising pipelines. With the recent announcement of Valeant Pharmaceuticals (VRX) attempting a hostile takeover of Celphalon (CEPH), we have looked at other value names in the biotech sector that could be lucrative targets in the near future. We viewed...
-
Stocks Near Or Above 52-Week High (FAST, GWW, STJ, HSY, PGN, IRM, WPI, ADP, AA, MCO)
Wednesday, April 6, 2011 - 2:02pm | 239Fastenal (NASDAQ: FAST) is currently trading at $68.47, which is above the previous 52-week high of $66.78. W.W. Grainger (NYSE: GWW) is currently trading at $143.86, which is above the previous 52-week high of $142.32. St. Jude Medical (NYSE: STJ) is currently trading at $53.63, which is above...
-
Experts Think Merck's Gardasil Could Be Widely Distributed (MRK)
Wednesday, April 6, 2011 - 12:59pm | 63According to a tweet from BlueShift Capital, Merck's (NYSE: MRK) Gardasil vaccine could be more widely distributed and used after a recent study by H Lee Moffitt Cancer Center. This is according to experts in the industry. Shares of Merck are up 22 cents to $33.38, a gain of 0.66%.
-
Early Afternoon Biggest Percentage Gainers And Losers (HILL, ABAT, SIMO, BLTI, DYSL, AMSC, XNPT, PUDA, VHC, SCOK)
Wednesday, April 6, 2011 - 12:05pm | 338Best 1) Dot Hill Systems (NASDAQ: HILL): The stock is currently trading up over 20% to $3.27 after the company reported that it will be launching a new video storage product. 2) Advanced Battery Technologies (NASDAQ: ABAT): After starting out the day in negative territory, shares have...